Anacor Pharma Submits NDA For Topical Antifungal Drug Tavaborole - Quick Facts

(RTTNews) - Biopharmaceutical company, Anacor Pharmaceuticals (ANAC), Monday said it submitted a New Drug Application or NDA for its first drug tavaborole, for the topical treatment of onychomycosis, to the U.S. Food and Drug Administration or FDA. Onychomycosis is a fungal infection of the nail and nail bed that affects about 35 million people in the US.

After achieving significant results on its primary and secondary endpoints in two Phase 3 pivotal studies of tavaborole to treat onychomycosis topically without concomitant debridement, the submission of the NDA is a milestone achievement, Anacor said in a statement.